Extent and nature of duplication in PROSPERO using COVID-19-related registrations: a retrospective investigation and survey

Ref ID 847
First Author L. Beresford
Journal BMJ OPEN
Year Of Publishing 2022
URL https://eprints.whiterose.ac.uk/195496/
Keywords • COVID
• Overlapping reviews/redundancy
• Protocols
• Living
• Non-Cochrane reviews
Problem(s) • Redundant / overlapping / duplicated review question; leads to research waste
Article Type Empirical
Article Subtype Cross-sectional survey/Methodological systematic review
First Author Country United Kingdom
Aim To explore the extent of and reasons for duplication within PROSPERO registration records related to COVID-19, including whether the extent differed between rapid, full and living systematic reviews and/or particular areas of COVID-19-related research.
Level of Investigation Descriptive
Summary of Findings From 1054 COVID-19 systematic reviews registered in PROSPERO between March 2020 and January 2021. 138/1954 were submitted when at least one similar protocol was already registered in PROSPERO. Duplication was greatest in reviews of COVID-19 treatments. There were 41 responses from 138 authors invited to take part in the survey. Most respondents said that they identified similar reviews when they searched PROSPERO prior to registration. Main reasons given for ‘duplication’ were differences in PICOS or planned analyses (n=13), poor quality of previous registrations (n=2) and the need to update evidence (n=3). The authors of the study also identified full systematic reviews registered after living systematic reviews on the same topic.
Number of systematic reviews included 1054
Number of eligible systematic reviews assessed 3013
Treatment impacted No
Treatment impacted description
Interpretation impacted Not Applicable
Interpretation impacted description